Echolucent implants

Patent metadata

Field	Value
Publication number	US-2020206366-A1
Application number	US-202016817297-A
Country	US
Kind code	A1
Filing date	Mar 12, 2020
Priority date	Dec 15, 2009
Publication date	Jul 2, 2020
Grant date	—

Abstract

Echolucent implantable compositions are described. Applications include materials for delivering of therapeutic agents to a tissue at a placement site.

First claim

1 . A pharmaceutically acceptable implant composition comprising:
a collection of covalently-crosslinked hydrolytically biodegradable hydrogel particles, a therapeutic agent, and an osmotic agent, wherein the pharmaceutically acceptable implant composition is echolucent.

2 . The pharmaceutically acceptable implant composition of claim 1 further comprising a radiopaque agent.

3 . The pharmaceutically acceptable implant composition of claim 2 wherein the radiopaque agent is covalently attached to a plurality of the hydrogel particles in the collection.

4 . The pharmaceutically acceptable implant composition of claim 1 wherein the collection comprises hydrogel particles having an average diameter from about 10 microns to about 500 microns.

5 . The pharmaceutically acceptable implant composition of claim 1 wherein the collection comprises hydrogel particles having an average diameter from about 125 microns to about 500 microns.

6 . The pharmaceutically acceptable implant composition of claim 1 further comprising an ultrasound contrast agent.

7 . The pharmaceutically acceptable implant composition of claim 1 wherein the therapeutic agent comprises a pain reliever, an anesthetic, a steroid, a chemotherapeutic agent, or combinations thereof.

8 . The pharmaceutically acceptable implant composition of claim 1 wherein a volume of the pharmaceutically acceptable implant composition increases no more than 50% upon exposure to an in vitro physiological saline solution or an in vivo environment in a tissue.

9 . The pharmaceutically acceptable implant composition of claim 1 wherein the collection has a time for complete degradation from about 7 days to about 180 days in an in vivo environment in a tissue.

10 . The pharmaceutically acceptable implant composition of claim 1 wherein the collection is hydrolytically biodegradable in vivo to produce degradation products that are absorbed into the circulatory system and cleared from the body via renal filtration.

11 . The pharmaceutically acceptable implant composition of claim 10 wherein the degradation products of the hydrogel particles in the collection comprise a polyethylene glycol covalently bound to a radiopaque agent, wherein the radiopaque agent comprises iodine.

12 . The pharmaceutically acceptable implant composition of claim 1 wherein the hydrogel particles in the collection are dehydrated.

13 . The pharmaceutically acceptable implant composition of claim 1 further comprising an amount of a pharmaceutically acceptable fluid wherein the pharmaceutically acceptable implant composition is a slurry that is deliverable through an applicator.

14 . The pharmaceutically acceptable implant composition of claim 1 wherein the osmotic agent comprises a linear hydrophilic polymer.

15 . The pharmaceutically acceptable implant composition of claim 1 wherein the osmotic agent comprises polyethylene glycol.

16 . The pharmaceutically acceptable implant composition of claim 1 wherein the hydrogel particles are degassed.

17 . The pharmaceutically acceptable implant composition of claim 1 wherein the pharmaceutically acceptable implant composition is deliverable to a tissue at a placement site through an applicator, and wherein the applicator comprises a syringe, a catheter, a needle, a cannula, a hollow wire, or combinations thereof.

18 . The pharmaceutically acceptable implant composition of claim 17 wherein the pharmaceutically acceptable implant composition is adherent to the tissue.

19 . The pharmaceutically acceptable implant composition of claim 1 further comprising a pharmaceutically acceptable fluid wherein the hydrogel particles and/or the pharmaceutically acceptable fluid comprise the therapeutic agent.

20 . The pharmaceutically acceptable implant composition of claim 1 wherein the therapeutic agent further comprises a surfactant, a lipid, a polyethylene glycol, or a distinct release rate modifying agent, or a combination thereof.

Assignees

• Incept Llc

Inventors

• Campbell Patrick
• Sawhney Amarpreet S

Classifications

• A61L27/50 Primary

  Materials characterised by their function or physical properties {, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials} · CPC title

• A61L27/58

  Materials at least partially resorbable by the body · CPC title

• A61K51/1244

  microparticles or nanoparticles, e.g. polymeric nanoparticles · CPC title

• A61L31/18

  Materials at least partially X-ray or laser opaque · CPC title

• A61K49/0419

  Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer · CPC title